RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
don't forget the VERTIS-CV Trial :D
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
Somewhat concurrently, MAVERICK was underway - mavacamten in non-obstructive #HCM and was presented at ACC 2020 , paper is here - https://t.co/93kMnNqFUh MAVERICK will inform the design of a phase III trial in non-obstructive #HCM
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: #ESCCongress Correction EXPLORER-HCM @TheLancet https://t.co/f51nD0CHK3
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: #ESCCongress Correction EXPLORER-HCM @TheLancet https://t.co/f51nD0CHK3
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
#ESCCongress Correction EXPLORER-HCM @TheLancet https://t.co/f51nD0CHK3
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
#ESCCongress Day 1 👇🏻👇🏻
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
#ESCCongress nice summary of Day 1 Web links to main publications 👇
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
RT @paomorejon: 📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-…
📌Day-1 #ESCCongress 📂ESST-AFNET4 @NEJM https://t.co/wMDXhUTo7C 📂EMPEROR-Reduced @NEJM https://t.co/rDYLHRnCVq 📂EXPLORER-HCM @JACCJournals https://t.co/vcQVVfQoS0 Summary by @AHAScience👇🏻 @paomorejon @DrMarthaGulati @rafavidalperez @AnastasiaSMihai @Sh
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the American College of Cardiology https://t.co/gUvIgryeeq
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @YaleCardiology: Mavacamten is well tolerated in most patients with nonobstructive hypertrophic cardiomyopathy according to a paper in @…
Mavacamten is well tolerated in most patients with nonobstructive hypertrophic cardiomyopathy according to a paper in @JACCJournals. #HCM 👉 https://t.co/YoTHMC7yLZ @YaleMed @YaleIMed @ericjvelazquez @MHBeasleyMD @DanielJacobyMD https://t.co/wmkCMpf0lb
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
MAVERICK-HCM explored the safety and efficacy of mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, in symptomatic non-obstructive HCM. Significant ⬇️ in NT-proBNP and cTnI, suggesting improvement in myocardial wall stress. htt
RT @JACCJournals: A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stre…
A new #JACC study finds mavacamten treatment was well tolerated and significantly reduced biomarkers of cardiac wall stress and injury in patients with hypertrophic #cardiomyopathy. https://t.co/DFRti2bjdd @MyoKardia https://t.co/oxQBHZB2xb
RT @MHBeasleyMD: Exciting news for patients with Hypertrophic Cardiomyopathy. Here's to hoping for the best in MAVERICK-HCM when clinical…
RT @Cardio_delaGuia: Improvement in Biomarkers of Cardiac Stress and Injury With #Mavacamten Treatment in Symptomatic Patients With Nonobst…
RT @Cardio_delaGuia: Improvement in Biomarkers of Cardiac Stress and Injury With #Mavacamten Treatment in Symptomatic Patients With Nonobst…
RT @Cardio_delaGuia: Improvement in Biomarkers of Cardiac Stress and Injury With #Mavacamten Treatment in Symptomatic Patients With Nonobst…
Improvement in Biomarkers of Cardiac Stress and Injury With #Mavacamten Treatment in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy #nHCM 🔽 A significant reduction in NT-proBNP and cTnI (improvement myocardial wall stress) https://t.c
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
RT @AmitGoyalMD: Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in t…
Lusitropic 💊 for HCM? Mavacamten⬇️BNP & Tn in MAVERICK-HCM. Excited for EXPLORER-HCM. https://t.co/yrIacYW4WG Fits in the the "PREVENT Symptoms" 🪣 of THE @cardionerds' 4⃣ Preventions of HCM ❤️🤓 https://t.co/qbhryvpBQA https://t.co/TVLp4Tm821
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @Michael_AlexO: Mavacamten mejora los biomarcadores de estrés cardiáco y lesión en la Miocardiopatía hipertrófica no obstructiva sintomá…
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy https://t.co/I1qGoYK1R9 @JACCJournals
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the American College of Cardiology https://t.co/IgwxrP1oY6
Mavacamten mejora los biomarcadores de estrés cardiáco y lesión en la Miocardiopatía hipertrófica no obstructiva sintomática. @ACCinTouch @SIAC_cardio @sccccardio @JACCJournals #Cardiology https://t.co/INXEcwEiFU https://t.co/VABnzRJbNy
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @mcmannello: Forever kudos to my mentor, friend, and (former 😢) boss @HeitnerStephen on this paper and all the hard work he, @MyoKardia,…
Non-obstructive Hypertrophic Cardiomyopathy : aim at lower contractility? https://t.co/Nv3qyk6eav #heart;#arrhythmias
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @mcmannello: Forever kudos to my mentor, friend, and (former 😢) boss @HeitnerStephen on this paper and all the hard work he, @MyoKardia,…
Forever kudos to my mentor, friend, and (former 😢) boss @HeitnerStephen on this paper and all the hard work he, @MyoKardia, and study teams nationwide have accomplished for our HCM patients via the mavacamten studies 👏🏻👏🏻👏🏻 @TrinaLowther @SchlichtingDave @